Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients
Mayorga Ayala, Luis (Hospital Universitari Vall d'Hebron)
Herrera-deGuise, Claudia (Hospital Universitari Vall d'Hebron)
Esperalba, Juliana (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Martinez-Gomez, Xavier (Hospital Universitari Vall d'Hebron)
Céspedes Martinez, Elena (Hospital Universitari Vall d'Hebron)
Serra Ruiz, Xavier (Hospital Universitari Vall d'Hebron)
Robles, Virginia (Hospital Universitari Vall d'Hebron)
Lastiri, Ernesto (Hospital Universitari Vall d'Hebron)
Perez, Zahira (Hospital Universitari Vall d'Hebron)
Oller, Elena (Hospital Universitari Vall d'Hebron)
Fernandez-Naval, Candela (Hospital Universitari Vall d'Hebron)
Martínez Gallo, Mónica (Hospital Universitari Vall d'Hebron)
Casellas, Francesc (Hospital Universitari Vall d'Hebron)
Borruel, Natalia (Hospital Universitari Vall d'Hebron)

Data:	2025
Resum:	Background : Studies investigating the long-term cellular immune response to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD) remain limited, particularly among those receiving immunosuppressive therapy. Methods : We prospectively evaluated humoral and cellular immune responses at short-term (4-6 weeks) and long-term (6-12 months) time points following SARS-CoV-2 mRNA vaccination in patients with IBD receiving anti-TNF agents, thiopurines, or combination therapy. We defined the short-term response as the measurement taken 4-6 weeks after the second vaccine dose and the long-term response as the measurement taken between 6 and 12 months after the first determination. A cohort of healthy controls was included for short-term comparative analysis. Results : At long-term follow-up, quantitative humoral responses were reduced in patients receiving anti-TNF monotherapy. In contrast, a reduced quantitative cellular response was found in the thiopurine (median 0. 7 UI/mL, p < 0. 05) and anti-TNF combo groups (median 0. 4 UI/mL, p < 0. 01) compared to anti-TNF monotherapy (median 2. 2 UI/mL). Conclusions : There was a robust long-term humoral and cellular response to vaccination, but a diminished quantitative cellular response in patients treated with thiopurines or combo therapy compared to anti-TNF monotherapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	SARS-CoV2 vaccine ; Inflammatory bowel disease ; Cellular response ; Thiopurines
Publicat a:	Cells, Vol. 14 Num. 15 (July 2025) , ISSN 2073-4409

DOI: 10.3390/cells14151156
PMID: 40801589

12 p, 634.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats